Healthy Joints

Joint Health

Keeping joints healthy can help prevent long-term damage from repeated bleeding episodes. Strong joints and limited bleeds are two important things you can do to keep your joints healthy.

Keep Joints Strong

Exercise and physical activity are important for joint health, helping you by:

Making muscles stronger, which may reduce bleeding episodes in joints
Maintaining balance, which will help prevent injuries from falls
Keeping a healthy weight by burning calories, which means less stress on the joints

Limit the Impact of Bleeds

When you treat bleeds quickly and aggressively, you are limiting the impact of bleeds by slowing or stopping the progression of damage.

Your HTC can help you develop a plan for regular activity that will be safe and effective for you. Your health care team can also help you be prepared with the skills and resources to treat bleeds as soon as possible.

INDICATIONS

NovoSeven^® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

IMPORTANT SAFETY INFORMATION

The most common side effects in people taking NovoSeven^® RT were fever, bleeding, injection site reaction, joint pain, headache, high or low blood pressure, nausea, vomiting, pain, swelling, and rash. The most serious side effects observed during NovoSeven^® RT therapy are thrombotic events, which is when clots form in blood vessels and cause harm.
After taking NovoSeven^® RT, some patients have more of a risk of thrombotic events. Although the extent of this risk is not known, it is thought to be small. Some patients have conditions that may increase this risk. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury, a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they are taking NovoSeven^® RT may be at increased risk for thrombotic events.
People who have ever had a bad reaction to proteins from mice, hamsters, or "bovines" (such as an ox or cow) should consult their physician prior to using NovoSeven^® RT.
Serious adverse events which may have been related to the use of NovoSeven^® RT occurred in 14 of the 298 patients in the initial clinical program.
Some patients with Factor VII deficiency have developed resistance (antibodies) to Factor VII after treatment with NovoSeven^® RT. These patients had been previously treated with human plasma and/or plasma-derived Factor VII. Factor VII-deficient patients should be monitored for antibody formation before and after administration of NovoSeven^® RT.
Concomitant use of NovoSeven^® RT with other formulations of NovoSeven^® is not recommended due to potential dosing errors resulting from different from different concentrations.

Please click here for NovoSeven^® RT Prescribing Information

Please click here for original NovoSeven^® Prescribing Information

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven is a registered trademark of Novo Nordisk Health Care AG.
© 2009 Novo Nordisk Inc. 135550R5 June 2009